Back to results
US 2006/0142240 A1Published application
Mutagenic nucleoside analogs for the treatment of viral disease
AssigneeKoronis Pharmaceuticals, Incorporated
InventorsLing Li, Alexander Gall, Richard Daifuku
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs.
Claims24
-49. (canceled)
A method of increasing the mutation rate of a virus, comprising administering the compound to a virally infected cell, wherein the compound has the structure:
- wherein,
- R13, R14 and R15 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- R16 is a member selected from H and a sugar residue, which is in a configuration selected from D-, L- and combinations thereof;
- and in an anomeric form selected from α-, β- and combinations thereof;
- A and B are members independently selected from N, and CR17,
- wherein
- R17 is a member selected from H, OH, CN, N3, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, halogen NR18, and SR19,
- wherein
- R18 and R19 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- and wherein the compound is incorporated by a polymerase into a genomic nucleic acid encoding the virus, thereby inducing the virus to mutate.
7 more elements
-79. (canceled)
A compound having the structure:
- wherein,
- R13, R14 and R15 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- R16 is a member selected from H and a sugar residue, which is in a configuration selected from D-, L- and combinations thereof;
- and in an anomeric form selected from α-, β- and combinations thereof;
- A and B are members independently selected from N, and CR17,
- wherein
- R17 is a member selected from H, OH, CN, N3, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, halogen NR18, and SR19,
- wherein
- R18 and R19 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
6 more elements
Dependencies are inferred from the claim text.